drugset / Trial / NCT03901573
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)
Timeline
- Start
- 2019-12-26
- Primary completion
- 2023-08-15
- Completion
- 2023-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NT-I7 | Protein / enzyme biologic | — | Intramuscular |
| Background | Atezolizumab | Monoclonal antibody | — | Intravenous |